Last reviewed · How we verify
TRELAGLIPTIN SUCCINATE
TRELAGLIPTIN SUCCINATE is a drug. It is currently FDA-approved (first approved 2015).
Trelagliptin succinate is a small molecule that inhibits dipeptidyl peptidase 4, a type of enzyme. It is used to treat type 2 diabetes mellitus.
At a glance
| Generic name | TRELAGLIPTIN SUCCINATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
Common side effects
Key clinical trials
- Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients (PHASE3)
- Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes (NA)
- Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes (NA)
- Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
- Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus (PHASE4)
- A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets (PHASE1)
- Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Long-term Study of SYR-472 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRELAGLIPTIN SUCCINATE CI brief — competitive landscape report
- TRELAGLIPTIN SUCCINATE updates RSS · CI watch RSS
Frequently asked questions about TRELAGLIPTIN SUCCINATE
What is TRELAGLIPTIN SUCCINATE?
TRELAGLIPTIN SUCCINATE is a Small molecule drug.
When was TRELAGLIPTIN SUCCINATE approved?
TRELAGLIPTIN SUCCINATE was first approved on 2015.
What development phase is TRELAGLIPTIN SUCCINATE in?
TRELAGLIPTIN SUCCINATE is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing